Recent advances in cellular therapy for malignant lymphoma
Publication type: Journal Article
Publication date: 2021-08-01
scimago Q1
wos Q2
SJR: 1.007
CiteScore: 6.1
Impact factor: 3.2
ISSN: 14653249, 14772566
PubMed ID:
33558145
Cancer Research
Oncology
Cell Biology
Immunology
Immunology and Allergy
Transplantation
Genetics (clinical)
Abstract
Cellular therapies for malignant lymphoma include autologous or allogeneic hematopoietic stem cell transplantation (HSCT) and adaptive cellular therapy using EBV-specific T cells, cytokine-induced killer (CIK) cells, NKT cells, NK cells, chimeric antigen receptor T (CAR-T) cells and chimeric antigen receptor NK (CAR-NK) cells. In this review we discusses recent advances of these cellular therapies and consider ways to optimize these therapies. Not only a single strategy using one of these cellular therapies, but also multi-disciplinary treatment combines with antibodies, such as an anti-tumor antibody and an immune checkpoint antibody, may be more effective for relapsed and refractory lymphoma.
Found
Nothing found, try to update filter.
Found
Nothing found, try to update filter.
Top-30
Journals
|
1
|
|
|
Vaccines
1 publication, 10%
|
|
|
Nanomaterials
1 publication, 10%
|
|
|
Frontiers in Oncology
1 publication, 10%
|
|
|
Advanced Biology
1 publication, 10%
|
|
|
Medical Oncology
1 publication, 10%
|
|
|
In Vitro Cellular and Developmental Biology - Animal
1 publication, 10%
|
|
|
Biomarker Research
1 publication, 10%
|
|
|
Blood Research
1 publication, 10%
|
|
|
Journal of Immunology
1 publication, 10%
|
|
|
Naunyn-Schmiedeberg's Archives of Pharmacology
1 publication, 10%
|
|
|
1
|
Publishers
|
1
2
3
4
5
|
|
|
Springer Nature
5 publications, 50%
|
|
|
MDPI
2 publications, 20%
|
|
|
Frontiers Media S.A.
1 publication, 10%
|
|
|
Wiley
1 publication, 10%
|
|
|
Oxford University Press
1 publication, 10%
|
|
|
1
2
3
4
5
|
- We do not take into account publications without a DOI.
- Statistics recalculated weekly.
Are you a researcher?
Create a profile to get free access to personal recommendations for colleagues and new articles.
Metrics
10
Total citations:
10
Citations from 2024:
5
(50%)
Cite this
GOST |
RIS |
BibTex |
MLA
Cite this
RIS
Copy
TY - JOUR
DO - 10.1016/j.jcyt.2020.12.007
UR - https://doi.org/10.1016/j.jcyt.2020.12.007
TI - Recent advances in cellular therapy for malignant lymphoma
T2 - Cytotherapy
AU - TANAKA, JUNJI
PY - 2021
DA - 2021/08/01
PB - Elsevier
SP - 662-671
IS - 8
VL - 23
PMID - 33558145
SN - 1465-3249
SN - 1477-2566
ER -
Cite this
BibTex (up to 50 authors)
Copy
@article{2021_TANAKA,
author = {JUNJI TANAKA},
title = {Recent advances in cellular therapy for malignant lymphoma},
journal = {Cytotherapy},
year = {2021},
volume = {23},
publisher = {Elsevier},
month = {aug},
url = {https://doi.org/10.1016/j.jcyt.2020.12.007},
number = {8},
pages = {662--671},
doi = {10.1016/j.jcyt.2020.12.007}
}
Cite this
MLA
Copy
TANAKA, JUNJI. “Recent advances in cellular therapy for malignant lymphoma.” Cytotherapy, vol. 23, no. 8, Aug. 2021, pp. 662-671. https://doi.org/10.1016/j.jcyt.2020.12.007.